Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 5Prostatic Neoplasms 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Hemangiosarcoma 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × balstilimab × Clear all
NCT05205330 2025-10-29

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Rottapharm Biotech

Phase 1/2 Active not recruiting
107 enrolled
Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡